US Insulin Pump Market to Reach USD 3.8 Bn by 2022, Expects DPI Research in Its New Report Now Available at MarketPublishers.com
21 Jul 2017 • by Natalie Aster
LONDON – The US market for insulin pumps is projected to amount to USD 3.8 billion by 2022-end.
The key factors fuelling the sector’s growth and expansion include the increasing pool of diabetic patients, rising awareness of diabetes, enhanced glycemic control and flexible, lifestyle-compatible methods of treatment, as well as technological advances in insulin pump devices. Meantime, high prices for insulin pump devices are projected to hinder the growth of the marketplace in the offing.
Medtronic, Insulet Corporation, Roche, Tandem Diabetes Care and Animas Corporation are the dominant players in the marketplace.
New study “United States Insulin Pump Market” drawn up by DPI Research & Marketing Solutions presents an in-depth, thorough assessment of the market on a national level. The report offers an all-round examination of the type 1 (T1D), type 2 (T2D) and newly diagnosed T1D and total diabetes population. It gives deep insights into insulin pump users, specifically focusing on T1D and T2D insulin pump users. The report provides market outlook to 2022 by value, based on actual and prospective trends. It includes an analysis of clinical studies and the most favoured insulin pump brand by the patients; canvasses major trends with respect to partnerships, collaborations, and license agreements. The report also investigates essential growth propellers and restraints of the country’s insulin pump marketplace. The research also provides granular profiles of the leading market players, which are evaluated on such parameters as company overview, sales analysis and product outlook during 2011-2022.
Many more new reports by DPI Research can be found in the publisher’s catalogue at MarketPublishers.com.